DMK PHARMACEUTICALS CORPORATION
NASDAQ: DMK (DMK Pharmaceuticals Corporation)
Last update: 15 hours ago0.609
0.00 (-0.60%)
AIStockmoo Score
| Value | NA |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Return on Capital info | NA |
| Financial Health info | NA |
| Earnings Trend info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing | NA |
| From our AI technical analysis of the chart. info | NA |
| Trend Strength info | NA |
| Technical Setup info | NA |
| Candle Patterns info | NA |
| Medium-Term Trend info | NA |
| Sentiment 100% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Holdings' Sentiment info | NA |
| News Mood info | NA |
| Smart Money | NA |
| Insider Activity info | NA |
| Institutional Flow info | NA |
| Short Interest info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| No pillar has a clear reading, so the score is unchanged. | |
| Not in score | |
| Price Volatility info | NA |
| No clear trend across the short, medium and long term. info | |
| No clear signal from support and resistance. info | |
| Final Score | 0.00 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | DMK Pharmaceuticals Corporation | - | - |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| DMK | 6 M | - | - | - | 0.0 |
| SUPN | 6 B | 27.84% | - | 1.59 | -1.0 |
| ANIP | 2 B | - | 13.74 | 2.57 | -0.1 |
| COLL | 783 M | - | 23.13 | 2.72 | 0.1 |
| TKNO | 480 M | - | - | - | 0.8 |
| AQST | 435 M | - | - | - | -1.7 |
Select this tab to load the latest available analysis.
|
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |